# Plasma proteomic profile reveals persistent immune activation in post-acute sequelae of SARS-CoV-2 infection

**Authors:** Serena Fineschi, Joakim Klar, Jens Schuster, Jonas Bergquist, Niklas Dahl

PMC · DOI: 10.3389/fimmu.2026.1775044 · Frontiers in Immunology · 2026-02-23

## TL;DR

A study of 92 people found that long-term SARS-CoV-2 effects involve ongoing immune system activity, marked by specific proteins in the blood.

## Contribution

The study identifies a consistent inflammatory protein signature in post-acute SARS-CoV-2 patients, suggesting persistent immune activation.

## Key findings

- 26 differentially expressed proteins were identified in PASC patients, including upregulated OSM and IL1RN.
- Persistent immune pathways like Inflammatory Response and IL-6/JAK/STAT3 were activated in PASC patients.
- STRING network analysis revealed a tightly connected cytokine-driven inflammatory module in PASC.

## Abstract

Plasma proteomic profiling of 92 individuals with Post-Acute Sequelae of SARS-CoV-2 infection (PASC), assessed a mean of 34 months after acute infection, revealed a distinct inflammatory signature. Using proximity extension assay technology, 358 proteins were quantified, identifying 26 differentially expressed proteins (DEPs) in PASC: 23 upregulated and 3 downregulated. The most upregulated proteins were Oncostatin M (OSM) and IL-1 receptor antagonist (IL1RN). Additional increases were observed in IL-6, IL-12B, IL-2, CCL22, CSF3, CSF1, and HLA-DRA, as well as proteins involved in tissue remodeling and angiogenesis such as ANGPTL2 and TGFA. Random forest analysis confirmed IL1RN, OSM, ANGPTL2, HLA-DRA, and CLEC4A as strong discriminators between patients and controls. Gene set enrichment analysis demonstrated activation of multiple immune pathways, including Inflammatory Response, TNF-α/NF-κB signaling, IL-6/JAK/STAT3, IL-2/STAT5, and Allograft Rejection, indicating persistent activation of innate and adaptive immunity. STRING network analysis highlighted a tightly connected cytokine-driven inflammatory module. Plasma spike protein levels did not differ between patients and controls, suggesting that PASC-related inflammation may persist independently of ongoing viral replication. Overall, the findings indicate a consistent low-grade inflammatory state in PASC without evidence for distinct biological subtypes.

## Linked entities

- **Genes:** OSM (oncostatin M) [NCBI Gene 5008], IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557], IL6 (interleukin 6) [NCBI Gene 3569], IL12B (interleukin 12B) [NCBI Gene 3593], IL2 (interleukin 2) [NCBI Gene 3558], CCL22 (C-C motif chemokine ligand 22) [NCBI Gene 6367], CSF3 (colony stimulating factor 3) [NCBI Gene 1440], CSF1 (colony stimulating factor 1) [NCBI Gene 1435], HLA-DRA (major histocompatibility complex, class II, DR alpha) [NCBI Gene 3122], ANGPTL2 (angiopoietin like 2) [NCBI Gene 23452], TGFA (transforming growth factor alpha) [NCBI Gene 7039], CLEC4A (C-type lectin domain family 4 member A) [NCBI Gene 50856]
- **Proteins:** IL6 (interleukin 6), IL12B (interleukin 12B), IL2 (interleukin 2), CCL22 (C-C motif chemokine ligand 22), CSF3 (colony stimulating factor 3), CSF1 (colony stimulating factor 1), HLA-DRA (major histocompatibility complex, class II, DR alpha), ANGPTL2 (angiopoietin like 2), TGFA (transforming growth factor alpha), CLEC4A (C-type lectin domain family 4 member A)
- **Diseases:** Post-Acute Sequelae of SARS-CoV-2 infection (MONDO:0100233)

## Full-text entities

- **Genes:** IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, CXCL11 (C-X-C motif chemokine ligand 11) [NCBI Gene 6373] {aka H174, I-TAC, IP-9, IP9, SCYB11, SCYB9B}, TNFSF11 (TNF superfamily member 11) [NCBI Gene 8600] {aka CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B}, PSMG3 (proteasome assembly chaperone 3) [NCBI Gene 84262] {aka C7orf48, PAC3, Pba3}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, CLEC4A (C-type lectin domain family 4 member A) [NCBI Gene 50856] {aka CD367, CLECSF6, DCIR, DDB27, HDCGC13P, LLIR}, CXCL5 (C-X-C motif chemokine ligand 5) [NCBI Gene 6374] {aka ENA-78, SCYB5}, SCGB3A2 (secretoglobin family 3A member 2) [NCBI Gene 117156] {aka LU103, PNSP1, UGRP1, pnSP-1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, ANGPTL2 (angiopoietin like 2) [NCBI Gene 23452] {aka ARP2, HARP}, PLAUR (plasminogen activator, urokinase receptor) [NCBI Gene 5329] {aka CD87, U-PAR, UPAR, URKR}, AMN (amnion associated transmembrane protein) [NCBI Gene 81693] {aka IGS2, PRO1028, amnionless}, RAB6A (RAB6A, member RAS oncogene family) [NCBI Gene 5870] {aka RAB6}, PKLR (pyruvate kinase L/R) [NCBI Gene 5313] {aka CNSHA2, PK1, PKL, PKRL, RPK}, LTA (lymphotoxin alpha) [NCBI Gene 4049] {aka LT, TNFB, TNFSF1, TNLG1E}, CXCL6 (C-X-C motif chemokine ligand 6) [NCBI Gene 6372] {aka CKA-3, GCP-2, GCP2, SCYB6}, EPO (erythropoietin) [NCBI Gene 2056] {aka DBAL, ECYT5, EP, MVCD2}, BCL2L11 (BCL2 like 11) [NCBI Gene 10018] {aka BAM, BIM, BOD}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, FLT3LG (fms related receptor tyrosine kinase 3 ligand) [NCBI Gene 2323] {aka FL, FLG3L, FLT3L, IMD125}, NCF2 (neutrophil cytosolic factor 2) [NCBI Gene 4688] {aka NCF-2, NOXA2, P67-PHOX, P67PHOX}, PTPRM (protein tyrosine phosphatase receptor type M) [NCBI Gene 5797] {aka PTPRL1, R-PTP-MU, RPTPM, RPTPU, hR-PTPu}, MGLL (monoglyceride lipase) [NCBI Gene 11343] {aka HU-K5, HUK5, MAGL, MGL}, LAMP3 (lysosome associated membrane protein 3) [NCBI Gene 27074] {aka CD208, DC LAMP, DC-LAMP, DCLAMP, LAMP, LAMP-3}, LILRB4 (leukocyte immunoglobulin like receptor B4) [NCBI Gene 11006] {aka B4, CD85K, ILT-3, ILT3, LIR-5, LIR5}, CLEC4D (C-type lectin domain family 4 member D) [NCBI Gene 338339] {aka CD368, CLEC-6, CLEC6, CLECSF8, Dectin-3, MCL}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, CST7 (cystatin F) [NCBI Gene 8530] {aka CMAP}, CLEC7A (C-type lectin domain containing 7A) [NCBI Gene 64581] {aka BGR, CANDF4, CD369, CLECSF12, DECTIN1, SCARE2}, CCL22 (C-C motif chemokine ligand 22) [NCBI Gene 6367] {aka A-152E5.1, ABCD-1, DC/B-CK, MDC, SCYA22, STCP-1}, OSM (oncostatin M) [NCBI Gene 5008], STAT5A (signal transducer and activator of transcription 5A) [NCBI Gene 6776] {aka MGF, STAT5}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, HLA-DRA (major histocompatibility complex, class II, DR alpha) [NCBI Gene 3122] {aka HLA-DRA1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, AGRN (agrin) [NCBI Gene 375790] {aka AGRIN, CMS8, CMSPPD}, CSF3 (colony stimulating factor 3) [NCBI Gene 1440] {aka C17orf33, CSF3OS, GCSF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, EPHA1 (EPH receptor A1) [NCBI Gene 2041] {aka EPH, EPHT, EPHT1}, IDS (iduronate 2-sulfatase) [NCBI Gene 3423] {aka ID2S, MPS2, SIDS}, TGFA (transforming growth factor alpha) [NCBI Gene 7039] {aka TFGA}, IL16 (interleukin 16) [NCBI Gene 3603] {aka LCF, NIL16, PRIL16, prIL-16}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TFF2 (trefoil factor 2) [NCBI Gene 7032] {aka SML1, SP}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, LGALS9 (galectin 9) [NCBI Gene 3965] {aka HUAT, LGALS9A}, CD83 (CD83 molecule) [NCBI Gene 9308] {aka BL11, HB15}, LTBR (lymphotoxin beta receptor) [NCBI Gene 4055] {aka D12S370, LT-BETA-R, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP}
- **Diseases:** ADHD (MESH:D001289), COVID (MESH:D000086382), post (MESH:D000094025), cardiovascular, cognitive, gastrointestinal, fatigue, (MESH:D005767), cardiovascular disease (MESH:D002318), infected (MESH:D007239), T cell dysregulation (MESH:D016399), Symptom (MESH:D012816), term disability (MESH:D000088562), Long COVID (MESH:D000094024), brain fog (MESH:D005222), cognitive dysfunction (MESH:D003072), Depression (MESH:D003866), muscle pain (MESH:D063806), malignancy (MESH:D009369), dyspnea (MESH:D004417), Anxiety (MESH:D001007), fibrosis (MESH:D005355), Inflammation (MESH:D007249), headache (MESH:D006261), pain (MESH:D010146), sleep disturbances (MESH:D012893), musculoskeletal pain (MESH:D059352), autoimmune (MESH:D001327), Fatigue (MESH:D005221)
- **Chemicals:** DEPs (-), Tocilizumab (MESH:C502936)
- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968220/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12968220/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968220/full.md

---
Source: https://tomesphere.com/paper/PMC12968220